Skip to main content
BJDX
NASDAQ Industrial Applications And Services

Bluejay Diagnostics Secures U.S. Manufacturing Partnership for Symphony™ Platform

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$2.18
Mkt Cap
$2.245M
52W Low
$1.623
52W High
$16.68
52W Position info
34% above low
Off High info
87% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

BJDX sits 34% above its 52-week low of $1.623.

Summary

Bluejay Diagnostics has partnered with Argonaut Manufacturing Services to establish U.S.-based manufacturing for its Symphony™ platform, a key move to support future commercialization and strengthen its supply chain.


Key Events · M&A and Partnerships · BJDX

  • Strategic Manufacturing Agreement

    Bluejay Diagnostics entered into a material definitive agreement with Argonaut Manufacturing Services for comprehensive manufacturing services for its Symphony™ platform, specifically IL-6 testing products.

  • U.S.-Based Production Established

    The partnership aims to establish scalable U.S.-based manufacturing capabilities, reducing reliance on overseas production and enhancing supply chain resilience.

  • Supports Commercialization Goals

    This move is critical for advancing Bluejay's clinical development programs and future commercialization objectives for its near-patient diagnostic solutions.

  • Addresses Operational Risk

    The agreement helps de-risk the company's operational foundation, which is vital given its current financial challenges and stated need for capital.


Analysis · BJDX · Industrial Applications And Services

This agreement with Argonaut Manufacturing Services is a critical step for Bluejay Diagnostics, establishing scalable U.S.-based manufacturing for its IL-6 testing products on the Symphony™ platform. For a company facing a going concern warning and needing significant capital, securing a robust domestic supply chain is essential for de-risking future commercialization efforts and potentially attracting necessary funding. It mitigates reliance on overseas manufacturing and supports ongoing clinical development.

How filings like this one have moved

In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BJDX was trading at $2.18 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.2M. The 52-week trading range was $1.62 to $16.68. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BJDX - Latest Insights

BJDX
Aug 13, 2026, 7:56 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.03
Real-time Price: $0.850 info
Change: -$0.180 (-17%) info
Market Cap: $3.798M info
BJDX
Aug 13, 2026, 6:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.05
Real-time Price: $0.850 info
Change: -$0.200 (-19%) info
Market Cap: $3.798M info
BJDX
Aug 12, 2026, 4:05 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.05
Real-time Price: $0.850 info
Change: -$0.200 (-19%) info
Market Cap: $3.798M info
BJDX
Jul 22, 2026, 5:25 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.14
Real-time Price: $0.850 info
Change: -$0.290 (-25%) info
Market Cap: $3.798M info
BJDX
Jul 21, 2026, 6:30 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $1.17
Real-time Price: $0.850 info
Change: -$0.320 (-27%) info
Market Cap: $3.798M info